PCVX Vaxcyte, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649094 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-74.8%
TTM EPS YoY-66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-42.7%
ROA-37.3%
ROIC (approx.)-39.1%
Asset turnover—
Leverage & solvency
Liabilities / assets16.7%
Debt / equity0.00x
Current ratio4.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $270.33M | $267.85M | $312.78M | $242.06M | $209.93M | $194.18M | $148.13M | $133.61M |
| SG&A expense | $37.95M | $34.92M | $33.07M | $32.22M | $32.45M | $32.04M | $32.66M | $28.55M |
| Operating income | -$308.27M | -$302.78M | -$345.85M | -$274.28M | -$242.38M | -$226.22M | -$180.79M | -$162.17M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$297.06M | -$284.30M | -$320.62M | -$246.51M | -$212.83M | -$166.57M | -$140.72M | -$137.08M |
| EBITDA | -$302.47M | -$299.77M | -$342.90M | -$266.79M | -$239.28M | -$223.34M | -$177.84M | -$159.31M |
| EPS (basic) | -1.99 | -1.97 | -2.30 | — | -1.56 | -1.22 | -1.04 | — |
| EPS (diluted) | -1.99 | -1.97 | -2.30 | — | -1.56 | -1.22 | -1.04 | — |
| Dividends declared per share | 0.00 | — | — | 0.00 | 0.00 | — | — | 0.00 |
| Weighted avg. shares (diluted) | 148.91M | 144.49M | 139.51M | — | 136.20M | 136.03M | 135.69M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $125.47M | $183.19M | $260.84M | $173.96M | $281.08M | $306.74M | $346.85M | $389.19M |
| Short-term investments | $1.17B | $1.30B | $1.48B | $1.39B | $1.43B | $1.35B | $1.32B | $1.36B |
| Current assets | $1.35B | $1.55B | $1.81B | $1.63B | $1.77B | $1.72B | $1.72B | $1.79B |
| PP&E, net | $253.36M | $260.39M | $260.69M | $257.37M | $253.49M | $242.27M | $217.16M | $198.04M |
| Total assets | $2.99B | $3.14B | $3.35B | $3.00B | $3.17B | $3.31B | $3.38B | $3.51B |
| Current liabilities | $295.70M | $271.28M | $242.08M | $205.75M | $200.05M | $154.49M | $97.00M | $140.18M |
| Total liabilities | $499.92M | $380.21M | $352.29M | $317.21M | $278.72M | $234.03M | $178.08M | $205.50M |
| Shareholders' equity | $2.49B | $2.76B | $3.00B | $2.69B | $2.89B | $3.07B | $3.20B | $3.31B |
| Shares outstanding | 149.30M | 144.79M | 144.31M | 131.06M | 130.03M | 129.82M | 128.94M | 124.89M |
| Cash flow statement | ||||||||
| Operating cash flow | -$224.08M | -$232.47M | -$280.62M | -$224.83M | -$143.31M | -$121.17M | -$166.27M | -$111.40M |
| Capital expenditure | $3.33M | $4.32M | $2.11M | $2.65M | $3.82M | $1.81M | $5.42M | $4.02M |
| Free cash flow | -$227.42M | -$236.79M | -$282.73M | -$227.49M | -$147.13M | -$122.98M | -$171.70M | -$115.42M |
| Investing cash flow | $170.77M | $147.72M | -$233.41M | $115.12M | $121.17M | $77.74M | $123.32M | -$557.17M |
| Financing cash flow | -$5.33M | $5.70M | $601.58M | $2.41M | -$3.67M | $2.52M | $759,000 | $4.91M |
| Depreciation & amortization | $5.80M | $3.00M | $2.95M | $7.50M | $3.10M | $2.88M | $2.96M | $2.86M |
| Stock-based compensation | $41.10M | $41.24M | $37.96M | $36.00M | $35.31M | $36.93M | $30.61M | $24.37M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.